Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib in First-line EGFR+ Non-squamous NSCLC
NCT03460275Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Feb 2018
- Primary completion
- Dec 2020
- Countries
- 1
01
Overview
A Phase 2 trial of osimertinib in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT03460275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03460275.